| 引用本文：安舒涵,向婧,蔡梦娜,等.中成药集中带量采购中选及价格下降的影响因素研究——以湖北省为例[J].中国卫生政策研究,2025,18(3):74-80 |
|
| 中成药集中带量采购中选及价格下降的影响因素研究——以湖北省为例 |
| 投稿时间：2025-02-17 PDF全文浏览 HTML全文浏览 |
| 安舒涵,向婧,蔡梦娜,崔丹 |
| 武汉大学公共卫生学院 湖北武汉 430071 |
| 摘要:目的:分析前两批中成药集中带量采购是否中选及价格差额/降幅的影响因素,为完善中成药集采政策提供依据。方法:选取前两批中成药集采产品为研究对象,分别采用Logistic回归和多元线性回归分析是否中选和中选后价格差额/降幅的影响因素。结果:医疗机构认可度高、属于基本药物的中成药中选概率更大；市场占有率超过50%的企业产品在第一批集采中的中选概率更大。第一批集采中,注射剂、属于基药目录的药品价格差额更大；市场占有率低、医疗机构认可度低、A竞争单元和同竞争单元内企业数量多的价格降幅更大。第二批集采中,注射剂、具备中药材生产资质的价格差额更大；B竞争单元的价格降幅更大。结论:中成药集采“保质”与“降价”两手抓,集采方案逐步完善,减少对大企业的倾斜,实现中成药集采“触底价”。但当前仍需从质量认定、公平竞争等入手,与中药饮片集采充分联动,推动中成药集采行稳致远。 |
| 关键词:中成药 药品集中带量采购 价格降幅 影响因素 回归分析 |
| 基金项目:国家自然科学基金青年科学基金项目(72404098) |
|
| Study on the influencing factors of selection and price decline in the centralized volume-based purchase of Proprietary Chinese Medicine:Taking Hubei Province as an example |
| AN Shu-han, XIANG Jing, CAI Meng-na, CUI Dan |
| School of Public Health, Wuhan University, Wuhan Hubei 430071, China |
| Abstract:Objective:Analyse the factors affecting whether the first two batches of centralized volume-based purchase of Proprietary Chinese Medicine were selected, the price difference and the rate of reduction, so as to provide a basis for improving the policy of centralized volume-based purchase of Proprietary Chinese Medicine.Methods:The first two batches of centralized volume-based purchase of Proprietary Chinese Medicine were selected for the study. Logistic regression was used to analyse the influencing factors of whether the selection was won or not. Multiple linear regression was used to analyse the influencing factors of price difference/reduction after being selected. Results:Proprietary Chinese Medicine with a high degree of acceptance by medical institutions and belonging to the category of essential medicines have a higher probability of being selected. The probability of selected products in the first batch of centralised purchase is greater for enterprises with a market share of more than 50%. In the first batch of centralized volume-based purchase of Proprietary Chinese Medicine, the price difference of injections and medicines belonging to the catalogue of essential medicines is greater. Price reductions were greater for those with low market share, low recognition by medical institutions, and a large number of enterprises in the A-competition unit and the same competition unit. In the second batch of centralised volume-based purchase of Proprietary Chinese Medicine, the price difference is greater for injections, and those with qualifications for the production of Chinese herbal medicines. the price reduction is greater in the B competitive unit.Conclusion:The centralized volume-based purchase of Proprietary Chinese Medicine has been both ‘quality-assured’ and ‘price-reduced’. The centralized volume-based purchase of Proprietary Chinese Medicine has been gradually improved, and the tilt towards large enterprises has been reduced, so that the centralized volume-based purchase of Proprietary Chinese Medicine can achieve a ‘bottom price’. However, it is still necessary to start from the quality of identification, fair competition, and so on, and the centralized volume-based purchase of Proprietary Chinese Medicine fully linked to promote the centralized purchase of Traditional Chinese Medicine Decoction Pieces to a stable and far-reaching. |
| Key words:Proprietary Chinese Medicine Centralized volume-based drug purchase Price reduction Influencing factors Regression analysis |
| 摘要点击次数: 41 全文下载次数: 12 |
|
|
|
|
|
